Clinical trials aiming to validate the therapeutic benefit observed with preclinical CSF-1R-PD-1 dual inhibition using both small molecule (NCT02452424) and monoclonal antibody inhibitors (NCT02526017 and NCT02323191) are assessing responses in patients with neuroblastoma. This evidence concerns the gene CSF1R and neuroblastoma.